Big Demand for (Free) Obesity Drugs

Orexigen's (Nasdaq: OREX  ) Light Study hasn't been light on the enrollment. Yesterday, the company said the safety study for its obesity drug Contrave has recruited more than 4,500 patients and is now on target to close enrollment by the end of the year.

You'll recall that the Food and Drug Administration rejected Contrave in 2011, requesting a cardiovascular outcomes trial to rule out possible heart problems. The agency originally wanted a humongous trial, but later conceded that a smaller trial would suffice. With the quick enrollment, Orexigen is gaining ground on Arena Pharmaceuticals (Nasdaq: ARNA  ) and VIVUS (Nasdaq: VVUS  ) , which got their obesity drugs approved this year; the biotech expects to be able to conduct an interim analysis of the safety data in 2013, which might be enough to resubmit to the FDA.

As a small conciliation for being behind, Orexigen has effectively taken the patients in the Light Study off the market as potential customers for the currently approved drugs. Vertex Pharmaceuticals (Nasdaq: VRTX  ) actually blamed the slowing sales of Incivek on hepatitis C patients choosing clinical trials over Incivek. But I don't think it'll be as big of an issue for Belviq or Qsymia; there are substantially more obese people in the U.S. than there are people with known hepatitis C infections.

The faster-than-expected enrollment for the Light Study is a clear sign that there's demand to pop a pill to lose weight, but there's a caveat: In the Light Study, patients get Contrave for free. Patients taking Arena's Belviq and VIVUS' Qsymia will have to pay for the drug. According to CNBC's Ruth Coxeter, the wholesale price of the Qsymia will be $120 per month and more for the higher dose.

That's a lot more than your average gym membership. Sure, popping a pill is less work, but substantial weight loss is going to come from diet and exercise combined with taking the medication. Lazy patients trying to take the easy way aren't likely to stay on the drug for very long if they're paying full price.

It seems to me that the key to getting Belviq and Qsymia to blockbuster status is to convince the insurance companies to cover the drugs. If patients are only paying the cost of their copay to get their medication each month, they might be willing to stay on the drug even if they're only experiencing minor weight loss.

Otherwise, expect light sales.

If you're interested in investing in revolutionary obesity treatments, make sure to check out our in-depth coverage of Arena Pharmaceuticals in this brand new premium research report. Complete with a year's worth of updates, this report will give you the investing edge you need, along with a full year of updates! Click here to get your copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 09, 2012, at 10:01 PM, genesis667 wrote:

    re:As a small conciliation for being behind, Orexigen has effectively taken the patients in the Light Study off the market as potential customers for the currently approved drugs.

    Are you serious? 4500 people off the market, gimme a break, there are 330 million people in the U.S alone, 35.7% of which are obese...Obesity costs $147 billion dollars in medical related expenses annually....You are living in a fantasy land!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2008805, ~/Articles/ArticleHandler.aspx, 9/22/2014 8:46:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASD 4,527.69 -52.10 -1.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/22/2014 3:59 PM
ARNA $4.10 Down -0.06 -1.44%
Arena Pharmaceutic… CAPS Rating: **
OREX $4.51 Down -0.26 -5.45%
Orexigen Therapeut… CAPS Rating: **
VVUS $4.25 Up +0.09 +2.16%
VIVUS, Inc. CAPS Rating: **
VRTX $104.71 Up +0.96 +0.93%
Vertex Pharmaceuti… CAPS Rating: ***

Advertisement